Locations:
What’s coming up at ASH and beyond
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Global R&D efforts expanding first-line and relapse therapy options for patients
A case study on the value of access to novel therapies through clinical trials
Two thirds of patients responded to CAR T-cell therapy
On-demand stem cell mobilizer is an effective salvage strategy
Dispelling myths and sharing practical experiences
Research indicates strong rationale for expanding trial eligibility criteria
Advertisement
Advertisement
Search